Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021)

Brief description of study

The purpose of the study is to determine the safety of the combination of trametinib (powder or tablet) and everolimus (tablet or dissolvable tablet) at different dose levels in pediatric and young adult patients with recurrent low-grade gliomas (LGGs). We want to find out what good and/or bad effects it has on you and your glioma as well as the chemistry of trametinib and everolimus when given in combination. We want to find a better treatment for controlling low-grade gliomas that have recurred and what good and/or bad effects it has on these patients. The study drug combination of trametinib and everolimus is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.

Clinical Study Identifier: s20-01427 Identifier: NCT04485559

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.